Form 4: Cassava Sciences Director Granted Stock Options Under New Compensation Plan

Cassava Sciences Inc. Director Patrick J. Scannon, MD PhD, was granted 26,500 stock options with an exercise price of $2.11, vesting over one year.

Summary

• Patrick J. Scannon, MD PhD, a Director of Cassava Sciences Inc. (SAVA), was granted 26,500 stock options.
• The stock options have an exercise price of $2.11 per share.
• The grant date for these options was May 23, 2025.
• The options are exercisable starting May 23, 2025, and expire on May 23, 2035.
• The grant was made pursuant to the Amended Non-employee Director Compensation Program, which was approved by stockholders on May 23, 2025.
• The stock options will vest over a one-year period at a rate of 1/12 per month.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents routine compensation that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The transaction is part of a stockholder-approved compensation program, indicating transparency and adherence to corporate governance practices.

Future Outlook

The stock options granted to the director will vest over a one-year period at a rate of 1/12 per month, indicating a future commitment and incentive structure for the director.

Management Comments

• The Form 4 represents a grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025.
• Stock options vest over a one (1) year period at a rate of 1/12 per month.

Industry Context

The grant of stock options to non-employee directors is a common practice across various industries, including biotechnology, to attract and retain qualified board members and align their long-term interests with company performance and shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of non-employee director compensation is a standard practice in the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Eli Lilly and Company, which often use equity-based incentives to align director interests with long-term R&D cycles and market milestones.
• The vesting schedule of 1/12 per month over one year is a common approach for director equity grants, ensuring continued engagement and commitment over a reasonable period, comparable to practices seen at many publicly traded life sciences firms.

Corporate Governance

Related Party Transactions

• The grant of stock options to Patrick J. Scannon, MD PhD, a Director of Cassava Sciences Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees mentioned, but it reinforces the company's compensation philosophy for key personnel.

Next Steps

• The stock options will continue to vest monthly over the next year.

Key Dates

Keywords

Cassava Sciences, SAVA, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Corporate Governance